Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.M. López-Cepero, A. Ferré, M. López, M. Salado, A. Benítez.
Azatioprina y carcinoma de cavum en un paciente afectado de hepatitis autoinmune y enfermedad de Crohn.
Gastroenterol Hepatol, 24 (2001), pp. 84
[2.]
A. Winkelstein.
The effects of azathioprine and 6-mercaptopurine on immunity.
J Immunopharmacol, 1 (1979), pp. 429-454
[3.]
C.E. Voogd.
Azathioprine, a genotoxic agent to be considered no genotoxic in man.
Mutation Res, 221 (1989), pp. 133-152
[4.]
D.J. Crawford, J.L. Maddocks, D.N. Jones, P. Szawlowski.
Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects.
J Med Chem, 39 (1996), pp. 2690-2695
[5.]
L. Lennard.
The clinical pharmacology of 6-mercaptopurine.
Eur J Clin Pharmacol, 43 (1992), pp. 329-339
[6.]
S. Ohlman, P. Lafolie, A. Lindholm, et al.
Large interindividual variability in bioavailability of azathioprine in renal transplant recipients.
Clin Transplant, 7 (1993), pp. 65-70
[7.]
L. Lennard, J.A. Van Loon, R.M. Weinshilboum.
Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphirsm.
Clin Pharmacol Ther, 46 (1989), pp. 149-154
[8.]
J.L. Snow, L.E. Gibson.
The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients.
Arch Dermatol, 131 (1995), pp. 193-197
[9.]
M. Relling, J.E. Rubnitz, G.K. Rivera, J.M. Boyett, M.L. Hancock, C.A. Felix, et al.
High incidence of secondary brain tumours after radiotherapy and antimetabolites.
Lancet, 354 (1999), pp. 34-39
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
